ClinicalTrials.gg
CompletedNCT05083260Updated Feb 8, 2023

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

A Phase 1/2 interventional study of NE3107 and placebo in Parkinson Disease, sponsored by BioVie Inc.. Completed at 16 sites in United States. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by BioVie Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
521st of 1,256
46 · median 36
Started
2022
with 104 others
Phase 1/2
51 of 1,649
11 open now
Registered
1,200th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 521st largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2022, is one of 51 in phase 1/2, and was the 1,200th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • MDS-UPDRS
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women at least 30 and no more 80 years of age
  2. Diagnosis of PD consistent with UK Brain Bank Criteria or MDS Research Criteria for the Diagnosis of PD, with bradykinesia and a clear motor response to levodopa
  3. Stable doses of all PD medications for at least 4 weeks prior to Screening
  4. Carbidopa/levodopa dose of at least 300 mg daily, distributed over a minimum of 3 dosing intervals during waking hours
  5. Participants must have history of motor fluctuations with reliable early-morning OFF episodes and a history of a good response to levodopa, in the judgement of the investigator
  6. If of , willing and able to use a highly effective form of during the study and for 30 days following last dose of study drug. Examples of highly effective forms of birth control are:

    1. Surgical sterility (via vasectomy, hysterectomy, or bilateral tubal ligation) or status in females
    2. Sexual partner who is sterile or of the same sex
    3. Double-barrier method (any combination of physical and chemical methods)
    4. Intrauterine device in females not containing hormones.
  7. Able and willing to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study
  8. Review Board/Ethics Committee-approved consent form signed and date by the participant
  9. Assessed as an appropriate and suitable candidate by the Enrollment Authorization Committee (EAC)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of secondary or atypical parkinsonism
  2. Severe or disabling fluctuations or dyskinesias that would, in the opinion of the investigator, interfere with completion of the study
  3. cognitive impairment
  4. Clinically significant hallucinations or delusions
  5. Clinically significant orthostatic hypotension
  6. Currently active major depression as determined by BDI-II score of >19
  7. Previous surgical procedure for PD (Duopa, DBS, etc.)
  8. History of small bowel or gastric surgery
  9. History of clinically significant GI abnormality (inflammatory bowel disease, significant motility disorder or emesis of any cause, etc.)
  10. Use of long-acting levodopa formulations (Sinemet CR, ER, Rytary, etc.)
  11. Routine use of proton pump inhibitors or H2 blockers
  12. Routine use of medications that may influence gastric motility (opiates, TCA antidepressants, anticholinergics, etc.)
  13. Other clinically significant medical, surgical, psychiatric, or laboratory abnormality that, in the judgment of the investigator, is likely to interfere with study compliance or assessment of safety or efficacy
    1. Evidence of significant hepatic impairment according to criteria, history of cirrhosis, and/or (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the (ULN), evidence of ascites, hepatic encephalopathy, greater than 2 mg/dL, albumin less than 2.0 g/dL, and of 1.5 and greater
  14. Significant renal impairment as determined by (CrCL) less than or equal to 50 mL/min
  15. Participant has an or clinical evidence of potentially unstable heart disease, including the following:

    1. > 470 msec females; > 450 msec males
    2. Complete right or left bundle branch block
    3. Ischemia or myocardial infarct within 1 year prior to the Screening Visit
    4. Clinically significant atrial or ventricular dysrhythmia; the heart must be in predominantly normal sinus rhythm
    5. Second- or third-degree AV block
    6. Heart failure of classification III or greater
    7. Serious cardiomyopathy or cardiac structural abnormality
    8. Symptomatic coronary artery or ischemic cardiac disease
    9. Any other cardiac condition that the Investigator feels may predispose the participant to ischemia or arrhythmia.
  16. Current (or within past 12 months) diagnosis or history of substance abuse, including alcohol (excluding nicotine or caffeine) by 5 criteria, or positive urine drug screen for tetrahydrocannabinol or any drugs that may affect participant safety or interfere with efficacy assessments
  17. Medical or recreational use of marijuana or CBD within 3 months of the Screening Visit
  18. Active suicidal ideation within 1 year prior to Screening Visit as determined by a positive response to Question 4 or 5 on the C-SSRS
  19. Currently lactating or pregnant, or planning to become pregnant during the study
  20. Current participation in another clinical study and/or receipt of any investigational drug within 90 days prior to screening
  21. Prior randomization into this study
  22. Diabetes requiring insulin treatment
  23. Use of potent inhibitors clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, and verapamil, and potent CYP2C9 and CYP2C19 inhibitors, amiodarone, fluconazole, miconazole, piperine, fluoxetine, fluvoxamine, and ticlopidine.
  24. History of breast cancer
  25. History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening. Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with efficacy assessments, based on the Investigator's clinical judgment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    NE3107

    orally administered NE3107 20 mg twice daily (BID)

    Drug: NE3107

  • Placebo comparator
    placebo

    orally administered placebo, twice daily

    Drug: placebo

Interventions

  • DrugNE3107

    NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease

  • Drugplacebo

    Hard gelatin capsule containing only common excipients for oral formulations

06

What researchers measure

Primary outcomes

  1. Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)

    Unified Parkinson's disease rating scale Part III total score is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each part scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease

    Time frame: measured on day 1, 2, 3, 14, and 28

  2. Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time)

    The total sum of time in which a patient self categorizes themselves as in the "off" state determined by diary entries. 0 hours is the minimum/best score, which indicates continuous L-dopa-like activity for the 24 hour period. 24 hours is the worst score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

    Time frame: off time will be measured/recorded every day from day 2 to day 27

  3. Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107

    An average score will be calculated from assessments of the Unified Parkinson's disease rating scale Part III total score, which is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease. Scores will be collected several times during the eight hours following L-dopa and/or NE3107 administration.

    Time frame: measured on day 1, 2, 3, 14, and 28

  4. Motor disease society- Unified Parkinson's disease rating scale Part I total score

    the cumulative score of a 13 question assessment of disease impact on patient's cognitive impairment, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease. This test asks about the impact of disease on cognition, but does not directly measure cognitive capability.

    Time frame: measured on day 1, 2, 3, 14, and 28

  5. Motor disease society- Unified Parkinson's disease rating scale Part 2 total score

    the cumulative score of a 13 question assessment of disease impact on patient's Motor Aspects of Experiences of Daily Living, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being a severe effect. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease.

    Time frame: measured on day 1, 2, 3, 14, and 28

  6. Change from baseline in the length of time during which L-dopa-like effects are felt by the patient

    The total sum of time in which a patient self categorizes themselves as in the "on" state, with or without dyskinesia determined by diary entries. 0 hours is the minimum/worst score, which indicates no L-dopa-like activity for the 24 hour period. 24 hours is the best score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

    Time frame: baseline and day 1, 2, 3, 14, and 28

  7. change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS)

    AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias (orofacial movements and extremity and truncal movements) in patients taking L-dopa. Questions assess the overall severity, incapacitation, and the patient's level of awareness of the movements, and distress associated with them. Questions are scored from 0 (no symptom) to 4 (severe). the minimum total score of 0 indicates no dyskinesia and the maximum total score of 48 indicates severe dyskinesia.

    Time frame: AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28

  8. change from baseline in time to onset of L-dopa-like activity

    Length of time from L-dopa administration to beginning of L-dopa activity producing "on-state". Patient self assessment of the time L-dopa-like activity begins after L-dopa administration. A decrease in the time to onset may shorten the time in the off-state and be considered a patient benefit. An increase in time to onset may lengthen time in the off-state and be considered a general worsening of response to treatment.

    Time frame: measured on Day 1, 2, 3, 14, and 28

  9. Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)

    The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients at all stages of PD. For each question, scores of severity (0 to 3, with 0 being none and 3 being major source of distress) and frequency (1 to 4, 1= rarely and 4 = very frequent) are recorded and the product of the two calculated. The sum of the products yields the overall score. The minimum total score of 0 indicates no non-motor symptoms and the maximum score of 360 indicates severe disease.

    Time frame: Measured on Day 1, 2, 3, 14, and 28

  10. change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107

    the plasma concentration vs time curve for L-dopa will be calculated from the L-dopa concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa area under the curve could be associated with changes in activity against motor symptoms of disease.

    Time frame: Blood samples will be collected on Day 1, 2, 3, and 14

  11. Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107.

    the maximum plasma concentration for L-dopa will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa Cmax could be associated with changes in activity against motor symptoms of disease.

    Time frame: Blood samples will be collected on Day 1, 2, 3, and 14

  12. The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered with

    the plasma concentration vs time curve for NE3107 will be calculated from the NE3107 concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours

    Time frame: Blood samples will be collected on Day 2, 3, and 14

  13. Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopa

    the maximum plasma concentration for NE3107 will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after NE3107 administration

    Time frame: Blood samples will be collected on Day 2, 3, and 14

07

Study locations

16 sites
  • Rocky Mountain Movement Disorders Center
    Englewood, Colorado 80113, United States
  • Parkinson's Disease & Movement Disorders Center Of Boca Raton
    Boca Raton, Florida 33486, United States
  • Velocity
    Hallandale Beach, Florida 33009, United States
  • Charter Research
    Lady Lake, Florida 32159, United States
  • Premier Clinical Research Institute
    Miami, Florida 33122, United States
  • First Excellent Research Group
    Miami, Florida 33172, United States
  • First Excellent Research
    Miami, Florida 33172, United States
  • EZY Medical Research
    Miami, Florida 33175, United States
  • Charter Research
    Winter Park, Florida 32792, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • New York Neurology Associates
    New York, New York 10003, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • M3 Wake Research
    Raleigh, North Carolina 27612, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • Texas Institute for Neurological Disorders
    Sherman, Texas 75092, United States
  • Inland Northwest Research
    Spokane, Washington 99202, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Nov 2022, 10 months.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 19, 2021
StartActual
Jan 4, 2022
Primary completionActual
Nov 21, 2022
CompletionActual
Jan 4, 2023
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05083260
Lead sponsor
BioVie Inc.
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Jan 4, 2022
Primary completion
Nov 21, 2022
Completion
Jan 4, 2023
Last update
Feb 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion